Equillium (EQ) Research Hub

Equillium (EQ) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.11 USD (-17.58%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.33, market cap 0.09B. This hub links to the full technical, earnings and options research available for EQ.

Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close2.11 USD (-17.58%)
52-week range1.98 USD – 3.54 USD
Trend regimeRange
14-day RSI50 (Neutral)
Trailing P/E-7.33
Market cap0.09B
Dividend yield0.00%
Next earnings2026-08-13

Available research for EQ

Earnings

EQ earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -7.33. Updated 2026-07-23.

Options: Covered Call

Covered Call on EQ: how it works, illustrative setup around the real 2.11 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on EQ: how it works, illustrative setup around the real 2.11 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on EQ: how it works, illustrative setup around the real 2.11 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

EQ technical analysis: range, last 2.11 USD, RSI 50, 52w range 1.98 USD–3.54 USD, real support/resistance. Updated 2026-09-11.

Frequently asked questions

What sector is EQ in?

Equillium (EQ) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is EQ in an uptrend or downtrend?

As of 2026-09-11, EQ is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is EQ's trailing P/E ratio?

EQ's trailing P/E is -7.33, with a market cap of 0.09B. See the earnings research page for full valuation detail.

When does EQ next report earnings?

EQ is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.05 USD.